The trial combines the first new TB drugs available in over 50 years with existing drugs to treat drug-resistant forms of the disease. Uzbekistan is among the top 27 countries with the highest rates of multidrug-resistant TB (MDR-TB).
We also treat children with TB with a shorter regimen of nine months, instead of the usual 12 months or more, and is conducting research into the results.
In the capital, Tashkent, we support the regional AIDS centre, with the aim of increasing access to diagnosis and care for patients living with HIV and treating co-infections.
We are currently responding to the coronavirus COVID-19 pandemic in the country.